Human Anti-ALK Antibody Product Attributes
ALK Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-ALK antibody staining is expected to be primarily localized to the plasma membrane.
Observed Antibody Staining Data By Tissue Type:
Variations in ALK antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in neuronal cells in the cerebral cortex and hippocampus and Purkinje cells in the cerebellum. More moderate antibody staining intensity was present in neuronal cells in the cerebral cortex and hippocampus and Purkinje cells in the cerebellum. Low, but measureable presence of ALK could be seen in cells in the endometrial stroma in endometrium, cells in the molecular layer in cerebellum, decidual cells in the placenta, endothelial cells in the cerebral cortex, epidermal cells in the skin, fibroblasts in mesenchymal tissue, germinal center cells in the lymph node, glandular cells in the adrenal gland, colon, endometrium, epididymis, fallopian tube, gallbladder, parathyroid gland, rectum, seminal vesicle and thyroid gland, hematopoietic cells in the bone marrow, Langerhans in skin, Leydig cells in the testis, macrophages in lung, myocytes in heart muscle and skeletal muscle, non-germinal center cells in the lymph node, ovarian stroma cells in the ovary, respiratory epithelial cells in the bronchus and nasopharynx, squamous epithelial cells in the cervix, uterine, oral mucosa and vagina, trophoblastic cells in the placenta and urothelial cells in the urinary bladder. We were unable to detect ALK in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of ALK expression as measured by anti-ALK antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal Intensity | + | – | – | + | + | + | + | + | + | – | + | – | + | ++ | – | + | + | + | + | + |
ALK Variability | + | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ | + | ++ | ++ | ++ | + | ++ | + | ++ |
ALK General Information | |
---|---|
Alternate Names | |
Anaplastic lymphoma kinase, ALK, ALK tyrosine kinase receptor, CD246, Cluster of Differentiation 246, ALK receptor tyrosine kinase | |
Molecular Weight | |
80kDa (hybrid) ;200kDa (wild type) | |
Chromosomal Location | |
2p23 | |
Curated Database and Bioinformatic Data | |
Gene Symbol | ALK |
Entrez Gene ID | 238 |
Ensemble Gene ID | ENSG00000171094 |
RefSeq Protein Accession(s) | NP_001340694, NP_004295 |
RefSeq mRNA Accession(s) | NM_001353765 XR_001738688, NM_004304 |
RefSeq Genomic Accession(s) | NC_018913, NC_000002, NG_009445 |
UniProt ID(s) | B6D4Y2, Q9UM73 |
UniGene ID(s) | B6D4Y2, Q9UM73 |
HGNC ID(s) | 427 |
Cosmic ID(s) | ALK |
KEGG Gene ID(s) | hsa:238 |
PharmGKB ID(s) | PA24719 |
General Description of ALK. | |
The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
There are no reviews yet.